9.40

3.07% 0.28

After Hours: 9.44 0.04 +0.43%

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $9.40, with a volume of 5.63M. It is up +3.07% in the last 24 hours and down -11.90% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$9.12

Open:

$9.28

24h Volume:

5.63M

Relative Volume:

0.93

Market Cap:

$2.88B

Revenue:

$32.77M

Net Income/Loss:

$-440.22M

P/E Ratio:

-4.1964

EPS:

-2.24

Net Cash Flow:

$-400.48M

1W Performance:

+15.48%

1M Performance:

-11.90%

6M Performance:

-6.09%

1Y Performance:

+69.98%

1-Day Range:

$9.17

$9.63

1-Week Range:

$7.98

$9.70

52-Week Range:

$5.41

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

557

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	9.40	2.88B	32.77M	-440.22M	-400.48M	-2.24
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

Nov 27, 2024

Is Iovance Biotherapeutics Stock a Millionaire Maker? - MSN

Nov 27, 2024

Nov 26, 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire

Nov 26, 2024

Iovance Biotherapeutics (STU:2LB) Operating Cash Flow per S - GuruFocus.com

Nov 26, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 68% return over 1 year, surging 10.0% in the last week alone - Simply Wall St

Nov 26, 2024

IOVA (Iovance Biotherapeutics) Total Assets : $991.12 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Victory Capital Management Inc. Has $1.36 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 26, 2024

Nov 25, 2024

IOVA (Iovance Biotherapeutics) Cash Flow from Financing : $389.32 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 24, 2024

Landscape Capital Management L.L.C. Takes $615,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 24, 2024

Eagle Asset Management Inc. Has $12.74 Million Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 24, 2024

Nov 23, 2024

Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back - Yahoo Finance

Nov 23, 2024